Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

Molecular pathogenesis and progression of prostate cancer.

Schrecengost R, Knudsen KE.

Semin Oncol. 2013 Jun;40(3):244-58. doi: 10.1053/j.seminoncol.2013.04.001. Review.

PMID:
23806491
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer.

Shiota M, Yokomizo A, Naito S.

Free Radic Biol Med. 2011 Oct 1;51(7):1320-8. doi: 10.1016/j.freeradbiomed.2011.07.011. Epub 2011 Jul 23. Review.

PMID:
21820046
[PubMed - indexed for MEDLINE]
3.

Androgen action in the prostate gland.

Yadav N, Heemers HV.

Minerva Urol Nefrol. 2012 Mar;64(1):35-49. Review.

PMID:
22402316
[PubMed - indexed for MEDLINE]
4.

Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines.

Marques RB, Dits NF, Erkens-Schulze S, van Ijcken WF, van Weerden WM, Jenster G.

PLoS One. 2011;6(8):e23144. doi: 10.1371/journal.pone.0023144. Epub 2011 Aug 4.

PMID:
21829708
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.

Nguyen MM, Wang Z.

Minerva Urol Nefrol. 2008 Mar;60(1):15-29. Review.

PMID:
18427432
[PubMed - indexed for MEDLINE]
6.

Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.

Vis AN, Schröder FH.

BJU Int. 2009 Aug;104(4):438-48. doi: 10.1111/j.1464-410X.2009.08695.x. Epub 2009 Jun 24. Review.

PMID:
19558559
[PubMed - indexed for MEDLINE]
7.

Androgen receptor variants occur frequently in castration resistant prostate cancer metastases.

Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, Vakar-Lopez F, Vessella RL, Plymate SR.

PLoS One. 2011;6(11):e27970. doi: 10.1371/journal.pone.0027970. Epub 2011 Nov 17.

PMID:
22114732
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer.

Knudsen KE, Penning TM.

Trends Endocrinol Metab. 2010 May;21(5):315-24. doi: 10.1016/j.tem.2010.01.002. Epub 2010 Feb 6. Review.

PMID:
20138542
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.

Xie N, Cheng H, Lin D, Liu L, Yang O, Jia L, Fazli L, Gleave ME, Wang Y, Rennie P, Dong X.

Int J Cancer. 2015 Feb 15;136(4):E27-38. doi: 10.1002/ijc.29147. Epub 2014 Aug 27.

PMID:
25138562
[PubMed - indexed for MEDLINE]
10.

The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer.

Chatterjee B.

Mol Cell Biochem. 2003 Nov;253(1-2):89-101. Review.

PMID:
14619959
[PubMed - indexed for MEDLINE]
11.

Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets.

Mellado B, Marin Aguilera M, Pereira MV.

Arch Esp Urol. 2013 Jun;66(5):453-62. Review.

PMID:
23793763
[PubMed - indexed for MEDLINE]
12.

New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.

Sharifi N.

Expert Opin Investig Drugs. 2010 Jul;19(7):837-46. doi: 10.1517/13543784.2010.494178. Review.

PMID:
20524793
[PubMed - indexed for MEDLINE]
13.

Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression.

Nyquist MD, Dehm SM.

Horm Cancer. 2013 Apr;4(2):61-9. doi: 10.1007/s12672-013-0131-4. Epub 2013 Jan 10. Review.

PMID:
23307762
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Advances in androgen receptor targeted therapy for prostate cancer.

Ahmed A, Ali S, Sarkar FH.

J Cell Physiol. 2014 Mar;229(3):271-6. doi: 10.1002/jcp.24456. Review.

PMID:
24037862
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Recent advances in understanding hormonal therapy resistant prostate cancer.

Donkena KV, Yuan H, Young CY.

Curr Cancer Drug Targets. 2010 Jun;10(4):402-10. Review.

PMID:
20464780
[PubMed - indexed for MEDLINE]
16.

TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.

Takayama K, Horie-Inoue K, Suzuki T, Urano T, Ikeda K, Fujimura T, Takahashi S, Homma Y, Ouchi Y, Inoue S.

Mol Endocrinol. 2012 May;26(5):748-61. doi: 10.1210/me.2011-1242. Epub 2012 Mar 28.

PMID:
22456197
[PubMed - indexed for MEDLINE]
17.

Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death.

Wen S, Niu Y, Lee SO, Chang C.

Cancer Treat Rev. 2014 Feb;40(1):31-40. doi: 10.1016/j.ctrv.2013.07.008. Epub 2013 Aug 7. Review.

PMID:
23993415
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

New hormonal therapies for castration-resistant prostate cancer.

Mostaghel EA, Plymate S.

Endocrinol Metab Clin North Am. 2011 Sep;40(3):625-42, x. doi: 10.1016/j.ecl.2011.05.013. Epub 2011 Jul 14. Review.

PMID:
21889725
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Old issues and new perspectives on prostate cancer hormonal therapy: the molecular substratum.

Reis LO.

Med Oncol. 2012 Sep;29(3):1948-55. doi: 10.1007/s12032-011-9991-z. Epub 2011 May 28. Review.

PMID:
21626233
[PubMed - indexed for MEDLINE]
20.

Androgen receptor: role and novel therapeutic prospects in prostate cancer.

Taplin ME.

Expert Rev Anticancer Ther. 2008 Sep;8(9):1495-508. doi: 10.1586/14737140.8.9.1495. Review.

PMID:
18759700
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk